IS2599B - 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess - Google Patents
3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þessInfo
- Publication number
- IS2599B IS2599B IS7470A IS7470A IS2599B IS 2599 B IS2599 B IS 2599B IS 7470 A IS7470 A IS 7470A IS 7470 A IS7470 A IS 7470A IS 2599 B IS2599 B IS 2599B
- Authority
- IS
- Iceland
- Prior art keywords
- phenylsulfonyl
- piperazin
- quinoline
- pharmaceutically acceptable
- acceptable derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207289A GB0207289D0 (en) | 2002-03-27 | 2002-03-27 | Novel compounds |
GB0225678A GB0225678D0 (en) | 2002-11-04 | 2002-11-04 | Novel compounds |
PCT/EP2003/003197 WO2003080580A2 (en) | 2002-03-27 | 2003-03-25 | Quinoline derivatives and their use as 5-ht6 ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
IS7470A IS7470A (is) | 2004-09-24 |
IS2599B true IS2599B (is) | 2010-04-15 |
Family
ID=28456035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7470A IS2599B (is) | 2002-03-27 | 2004-09-24 | 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess |
Country Status (28)
Country | Link |
---|---|
US (5) | US7452888B2 (is) |
EP (2) | EP1497266B1 (is) |
JP (2) | JP4455064B2 (is) |
KR (1) | KR101020399B1 (is) |
CN (1) | CN1315809C (is) |
AR (1) | AR039127A1 (is) |
AT (1) | ATE398108T1 (is) |
AU (1) | AU2003219103B2 (is) |
BR (1) | BRPI0308696B8 (is) |
CA (1) | CA2479786C (is) |
CY (2) | CY1108313T1 (is) |
DE (1) | DE60321558D1 (is) |
DK (2) | DK1956004T3 (is) |
ES (2) | ES2307919T3 (is) |
HK (1) | HK1074439A1 (is) |
IL (2) | IL164108A0 (is) |
IS (1) | IS2599B (is) |
MX (1) | MXPA04009318A (is) |
MY (1) | MY138836A (is) |
NO (1) | NO329319B1 (is) |
NZ (1) | NZ535239A (is) |
PL (1) | PL209872B1 (is) |
PT (2) | PT1956004E (is) |
RU (1) | RU2309154C9 (is) |
SI (2) | SI1497266T1 (is) |
TW (1) | TWI268928B (is) |
WO (1) | WO2003080580A2 (is) |
ZA (1) | ZA200407320B (is) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101020399B1 (ko) * | 2002-03-27 | 2011-03-08 | 글락소 그룹 리미티드 | 퀴놀린 유도체 및 5-ht6 리간드로서의 그의 용도 |
CN100422171C (zh) | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
TW200418830A (en) | 2003-02-14 | 2004-10-01 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
BRPI0412263B1 (pt) | 2003-07-22 | 2019-10-15 | Arena Pharmaceuticals, Inc. | Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição |
GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
GB0321473D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
GB0322510D0 (en) | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
GB0322629D0 (en) * | 2003-09-26 | 2003-10-29 | Glaxo Group Ltd | Novel compound |
GB0407025D0 (en) * | 2004-03-29 | 2004-04-28 | Glaxo Group Ltd | Novel compounds |
GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
GB0425548D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Radiolabelled ligands |
GB0426313D0 (en) * | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
BRPI0611516A2 (pt) | 2005-06-02 | 2010-09-14 | Hoffmann La Roche | 3-metanossulfonilquinolinas como realçadores ("enhancers") de gaba-b |
JP2009502853A (ja) * | 2005-07-27 | 2009-01-29 | エフ.ホフマン−ラ ロシュ アーゲー | アリールオキシキノリン類及び5−ht6モジュレーターとしてのその使用 |
GB0519758D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel process |
GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
ATE444069T1 (de) * | 2005-12-20 | 2009-10-15 | Richter Gedeon Nyrt | Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen |
MX2008012824A (es) | 2006-04-05 | 2008-10-15 | Wyeth Corp | Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6. |
CA2670717C (en) | 2007-01-08 | 2012-01-10 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
PE20090188A1 (es) * | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
UA97837C2 (ru) * | 2007-03-23 | 2012-03-26 | Эбботт Гмбх Унд Ко. Кг | Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-ht6 |
NZ581580A (en) | 2007-05-03 | 2011-03-31 | Suven Life Sciences Ltd | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
AU2008264999B8 (en) * | 2007-06-18 | 2013-10-31 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
WO2009019286A1 (en) * | 2007-08-07 | 2009-02-12 | Abbott Gmbh & Co. Kg | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
NZ585374A (en) | 2007-10-26 | 2011-09-30 | Suven Life Sciences Ltd | Amino arylsulfonamide compounds for treating disorders related to 5-HT6 receptor functions |
EP2254564A1 (en) * | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
CN101952278A (zh) * | 2008-02-15 | 2011-01-19 | 弗·哈夫曼-拉罗切有限公司 | 3-烷基-哌嗪衍生物及其用途 |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
JP5536781B2 (ja) | 2008-09-17 | 2014-07-02 | スヴェン・ライフ・サイエンシズ・リミテッド | アリールスルホンアミドアミン化合物および5−ht6リガンドとしてのそれらの使用 |
WO2010032257A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
UA107667C2 (uk) * | 2009-06-29 | 2015-02-10 | Аджиос Фармасьютікалз, Інк. | Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку |
LT2522658T (lt) * | 2010-01-04 | 2018-11-26 | Nippon Soda Co., Ltd. | Heterociklinis junginys, kurio sudėtyje yra azotas, ir žemės ūkio/sodininkystės germicidas |
EP2521714B1 (en) | 2010-01-05 | 2015-08-12 | Suven Life Sciences Limited | Aromatic sulfone compounds useful in the treatment of central nervous disorders |
RU2443697C1 (ru) * | 2010-12-21 | 2012-02-27 | Александр Васильевич Иващенко | Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения |
KR101250606B1 (ko) * | 2011-01-24 | 2013-04-03 | 이화여자대학교 산학협력단 | 5-ht6 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
AR086411A1 (es) | 2011-05-20 | 2013-12-11 | Nippon Soda Co | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria |
WO2013055386A2 (en) * | 2011-10-03 | 2013-04-18 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
RU2500672C1 (ru) * | 2012-10-25 | 2013-12-10 | Андрей Александрович Иващенко | (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения |
CN105452224B (zh) | 2013-04-02 | 2017-12-26 | 安基生技新药股份有限公司 | 作为抗神经退化剂的多官能性喹啉衍生物 |
US9302992B2 (en) | 2013-04-02 | 2016-04-05 | Annji Pharmaceutical Co., Ltd. | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
US20160324852A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
KR20180064373A (ko) | 2015-07-15 | 2018-06-14 | 엑소반트 사이언시즈 게엠베하 | 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체 |
AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
CN109069450A (zh) * | 2016-02-05 | 2018-12-21 | 法奈克斯公司 | 神经障碍的新的组合疗法 |
WO2017157929A1 (en) * | 2016-03-14 | 2017-09-21 | AbbVie Deutschland GmbH & Co. KG | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
CN108290842B (zh) * | 2016-05-27 | 2021-04-06 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的喹啉化合物及其药物组合物 |
WO2018102824A1 (en) * | 2016-12-02 | 2018-06-07 | Axovant Sciences Gmbh | Methods for treating neurodegenerative disease |
KR20210076224A (ko) | 2019-12-13 | 2021-06-24 | 주식회사 에피바이오텍 | 퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물 |
KR102281647B1 (ko) * | 2020-12-09 | 2021-07-30 | 메디케어제약 주식회사 | 피페라진-퀴놀린 유도체의 제조방법 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US708469A (en) * | 1901-08-27 | 1902-09-02 | George Lafayette Caldwell | Stroke-regulating mechanism for glass-presses, &c. |
JPH02262627A (ja) | 1988-12-08 | 1990-10-25 | Japan Synthetic Rubber Co Ltd | 有機非線形光学素子 |
SI9200377A (en) * | 1992-12-11 | 1994-06-30 | Krka | Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation |
GB9300147D0 (en) | 1993-01-06 | 1993-03-03 | Minnesota Mining & Mfg | Photothermographic materials |
GB9311790D0 (en) | 1993-06-08 | 1993-07-28 | Minnesota Mining & Mfg | Photothermographic materials |
US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
DK122693D0 (da) | 1993-10-29 | 1993-10-29 | Hempels Skibsfarve Fab J C | Marin struktur |
US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
AUPN842196A0 (en) | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
FR2750988B1 (fr) | 1996-07-11 | 1998-09-18 | Adir | Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
US20010051719A1 (en) * | 1996-12-19 | 2001-12-13 | Smithkline Beecham P.L.C. | Novel compounds |
EP0867477B1 (de) | 1997-03-25 | 2002-05-02 | Ciba SC Holding AG | Polycyclische Verbindungen |
AU7644698A (en) | 1997-04-22 | 1998-11-13 | Janssen Pharmaceutica N.V. | Crf antagonistic quino- and quinazolines |
AU751188C (en) | 1997-05-28 | 2005-06-30 | Aventis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6103905A (en) | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
HUP0003364A3 (en) * | 1997-06-19 | 2002-03-28 | Sepracor Inc Marlborough | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
US6207679B1 (en) | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
US6376670B1 (en) * | 1997-06-19 | 2002-04-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
TR200000073T2 (tr) | 1997-07-11 | 2000-06-21 | Smithkline Beecham P.L.C. | 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi |
DK0930302T3 (da) * | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
US6403808B1 (en) * | 1999-12-10 | 2002-06-11 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
CA2368455A1 (en) | 1999-03-29 | 2000-10-05 | Neurogen Corporation | 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
ATE375990T1 (de) | 1999-04-21 | 2007-11-15 | Nps Allelix Corp | Piperidin-indol derivate mit 5-ht6 affinität |
AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
MY125942A (en) | 1999-09-07 | 2006-09-29 | Upjohn Co | Aminoalkoxy carbazoles for the treatment of cns diseases |
AU1542201A (en) | 1999-11-05 | 2001-05-14 | Nps Allelix Corp. | Compounds having 5-HT6 receptor antagonist activity |
GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
US6310212B1 (en) * | 2000-03-28 | 2001-10-30 | Neurogen Corporation | 4-substituted quinoline derivatives |
PE20020063A1 (es) | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
GB0021450D0 (en) | 2000-08-31 | 2000-10-18 | Smithkline Beecham Plc | Novel compounds |
US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
BR0114253A (pt) | 2000-10-02 | 2003-07-01 | Janssen Pharmaceutica Nv | Antagonistas de receptor de glutamato metabotrópico |
WO2002032863A1 (en) | 2000-10-20 | 2002-04-25 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
AU2005102A (en) | 2000-11-02 | 2002-05-15 | Wyeth Corp | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
AU2002215047A1 (en) | 2000-11-21 | 2002-06-03 | Smithkline Beecham Plc | Isoquinoline derivatives useful in the treatment of cns disorders |
EP1335722B1 (en) | 2000-11-24 | 2006-08-30 | Smithkline Beecham Plc | Indolyl-sulfonyl- compounds useful in the treatment of cns disorders |
ES2188344B1 (es) | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
GB0111186D0 (en) | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
NZ529631A (en) * | 2001-06-07 | 2006-08-31 | F | Indole derivatives with 5-hydroxytryptamine (5-HT) 5-HT6 receptor affinity in the treatment of disorders of the CNS |
WO2002102774A1 (en) | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
ITRM20010356A1 (it) * | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
MXPA04001089A (es) | 2001-08-03 | 2004-05-20 | Upjohn Co | 5-arilsulfonil indoles que tienen afinidad por el receptor de 5-ht. |
EP1414442A1 (en) | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
KR100608417B1 (ko) | 2001-08-10 | 2006-08-02 | 에프. 호프만-라 로슈 아게 | 5-ht6 수용체 친화성을 갖는 아릴설포닐 유도체 |
JP2005504783A (ja) | 2001-08-31 | 2005-02-17 | ノバルティス アクチエンゲゼルシャフト | イロペリドン代謝産物の光学異性体 |
SE0103649D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
EP1456178A1 (en) | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
WO2003066056A1 (en) | 2002-02-05 | 2003-08-14 | Glaxo Group Limited | Method of promoting neuronal growth |
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
ATE323680T1 (de) * | 2002-02-13 | 2006-05-15 | Glaxo Group Ltd | 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen |
DE10207844A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
EP1478361A2 (en) | 2002-02-22 | 2004-11-24 | PHARMACIA & UPJOHN COMPANY | Arylsulfone derivatives |
KR101020399B1 (ko) * | 2002-03-27 | 2011-03-08 | 글락소 그룹 리미티드 | 퀴놀린 유도체 및 5-ht6 리간드로서의 그의 용도 |
JP2005527542A (ja) | 2002-03-27 | 2005-09-15 | グラクソ グループ リミテッド | キノリンおよびアザインドール誘導体およびその5−ht6リガンドとしての使用 |
CA2485136C (en) | 2002-05-13 | 2011-12-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
DE10221183A1 (de) | 2002-05-13 | 2003-12-04 | Max Planck Gesellschaft | Phosphatidyl-oligo-glycerine und Strukturanaloga |
PL374401A1 (en) | 2002-06-05 | 2005-10-17 | F.Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
SG156524A1 (en) | 2002-06-20 | 2009-11-26 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
ES2311721T3 (es) | 2002-09-17 | 2009-02-16 | F. Hoffmann-La Roche Ag | Indoles sustituidos en posicion 2,4 y su empleo como moduladores de 5-ht6. |
DK1587788T3 (da) | 2002-09-17 | 2007-09-24 | Hoffmann La Roche | 2,7-substituerede indoler og anvendelsen deraf som 5-HT6-modulatorer |
CN1309384C (zh) | 2002-10-18 | 2007-04-11 | 弗·哈夫曼-拉罗切有限公司 | 具有5-ht6受体亲和性的4-哌嗪基苯磺酰基吲哚 |
DE60318733T2 (de) | 2002-11-08 | 2009-01-15 | F. Hoffmann-La Roche Ag | Substituierte benzoxazinones und ihre verwendung |
TWI284124B (en) | 2002-12-03 | 2007-07-21 | Hoffmann La Roche | Aminoalkoxyindoles |
TW200418830A (en) * | 2003-02-14 | 2004-10-01 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2004078176A1 (en) | 2003-03-03 | 2004-09-16 | F. Hoffmann-La Roche Ag | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators |
GB0305575D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
TWI289141B (en) | 2003-03-11 | 2007-11-01 | Hoffmann La Roche F. Ag. | Quinolinone derivatives and uses thereof |
GB0320320D0 (en) | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
GB0322510D0 (en) | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
GB0322629D0 (en) | 2003-09-26 | 2003-10-29 | Glaxo Group Ltd | Novel compound |
GB0407025D0 (en) | 2004-03-29 | 2004-04-28 | Glaxo Group Ltd | Novel compounds |
GB0411421D0 (en) | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
GB0422263D0 (en) | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
GB0519765D0 (en) | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
GB0519760D0 (en) | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-03-25 KR KR1020047015297A patent/KR101020399B1/ko active IP Right Grant
- 2003-03-25 TW TW092106558A patent/TWI268928B/zh not_active IP Right Cessation
- 2003-03-25 AR ARP030101028A patent/AR039127A1/es not_active Application Discontinuation
- 2003-03-25 DE DE60321558T patent/DE60321558D1/de not_active Expired - Lifetime
- 2003-03-25 BR BRPI0308696A patent/BRPI0308696B8/pt not_active IP Right Cessation
- 2003-03-25 ES ES03714889T patent/ES2307919T3/es not_active Expired - Lifetime
- 2003-03-25 EP EP03714889A patent/EP1497266B1/en not_active Expired - Lifetime
- 2003-03-25 AT AT03714889T patent/ATE398108T1/de active
- 2003-03-25 NZ NZ535239A patent/NZ535239A/en not_active IP Right Cessation
- 2003-03-25 PT PT08157490T patent/PT1956004E/pt unknown
- 2003-03-25 DK DK08157490.7T patent/DK1956004T3/da active
- 2003-03-25 PT PT03714889T patent/PT1497266E/pt unknown
- 2003-03-25 IL IL16410803A patent/IL164108A0/xx unknown
- 2003-03-25 MX MXPA04009318A patent/MXPA04009318A/es active IP Right Grant
- 2003-03-25 DK DK03714889T patent/DK1497266T3/da active
- 2003-03-25 CN CNB038116448A patent/CN1315809C/zh not_active Expired - Fee Related
- 2003-03-25 EP EP08157490A patent/EP1956004B1/en not_active Expired - Lifetime
- 2003-03-25 PL PL374378A patent/PL209872B1/pl unknown
- 2003-03-25 CA CA2479786A patent/CA2479786C/en not_active Expired - Fee Related
- 2003-03-25 US US10/509,078 patent/US7452888B2/en not_active Expired - Lifetime
- 2003-03-25 WO PCT/EP2003/003197 patent/WO2003080580A2/en active IP Right Grant
- 2003-03-25 AU AU2003219103A patent/AU2003219103B2/en not_active Ceased
- 2003-03-25 MY MYPI20031054A patent/MY138836A/en unknown
- 2003-03-25 JP JP2003578335A patent/JP4455064B2/ja not_active Expired - Fee Related
- 2003-03-25 SI SI200331326T patent/SI1497266T1/sl unknown
- 2003-03-25 RU RU2004131641/04A patent/RU2309154C9/ru not_active IP Right Cessation
- 2003-03-25 SI SI200332178T patent/SI1956004T1/sl unknown
- 2003-03-25 ES ES08157490T patent/ES2386828T3/es not_active Expired - Lifetime
-
2004
- 2004-09-13 ZA ZA2004/07320A patent/ZA200407320B/en unknown
- 2004-09-14 IL IL164108A patent/IL164108A/en not_active IP Right Cessation
- 2004-09-24 IS IS7470A patent/IS2599B/is unknown
- 2004-10-25 NO NO20044588A patent/NO329319B1/no not_active IP Right Cessation
-
2005
- 2005-06-29 HK HK05105458A patent/HK1074439A1/xx not_active IP Right Cessation
-
2008
- 2008-09-03 CY CY20081100943T patent/CY1108313T1/el unknown
- 2008-09-05 US US12/205,079 patent/US7601837B2/en not_active Expired - Fee Related
-
2009
- 2009-05-25 JP JP2009125459A patent/JP5091913B2/ja not_active Expired - Fee Related
- 2009-08-14 US US12/541,456 patent/US7799774B2/en not_active Expired - Fee Related
-
2010
- 2010-07-30 US US12/847,039 patent/US7977337B2/en not_active Expired - Fee Related
-
2011
- 2011-06-03 US US13/152,356 patent/US8236947B2/en not_active Expired - Lifetime
-
2012
- 2012-09-05 CY CY20121100804T patent/CY1113306T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS2599B (is) | 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess | |
NO2022041I1 (no) | Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC | |
LUC00127I2 (fr) | Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro ) | |
IS7948A (is) | Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra | |
LU92517I2 (fr) | Delamanide et ses dérivés pharmaceutiquement acceptables | |
LU92513I2 (fr) | Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) | |
NO20041975L (no) | Bicyklisk oksopyridin og oksopyrimidinderivater | |
IS6385A (is) | Ný notkun og nýjar N-asabísýkló-amíð afleiður | |
NO20052524D0 (no) | Aminerte isofiavonoidderivater og anvendelse derav | |
ATE390426T1 (de) | Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate | |
ATE478870T1 (de) | Spiroindolinpiperidinderivate | |
ATE460418T1 (de) | Heterocyclocarboxamidderivate | |
ATE450506T1 (de) | Indol-3-schwefelderivate | |
ATE467631T1 (de) | Chinuclidinamidderivate | |
IS7720A (is) | Píperidín-N-oxíð-afleiður | |
DK2248807T3 (da) | N-Phenyl-2-pyrimidinaminderivater | |
IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
DK1513835T3 (da) | Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf | |
DK1590321T3 (da) | Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf | |
DE60307512D1 (de) | 3h-chinazoline -4-on derivaten | |
DK1556382T3 (da) | 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf | |
ATE423771T1 (de) | Tetrahydrochinolinderivate | |
DE50306277D1 (de) | 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate | |
DK1392670T3 (da) | Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater | |
IS7906A (is) | Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls |